Free Trial

Asensus Surgical Q4 2022 Earnings Report

Asensus Surgical logo
$0.35 0.00 (0.00%)
As of 08/22/2024

Asensus Surgical EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.07
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Asensus Surgical Revenue Results

Actual Revenue
$2.46 million
Expected Revenue
$2.50 million
Beat/Miss
Missed by -$40.00 thousand
YoY Revenue Growth
N/A

Asensus Surgical Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Asensus Surgical Earnings Headlines

9/9 on TSLA from June to January
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
See More Asensus Surgical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Asensus Surgical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Asensus Surgical and other key companies, straight to your email.

About Asensus Surgical

Asensus Surgical (NYSEAMERICAN:ASXC), a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

View Asensus Surgical Profile

More Earnings Resources from MarketBeat